These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 8804418

  • 21. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
    Høyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Danø K, Behrendt N.
    Biochem J; 2001 Sep 15; 358(Pt 3):673-9. PubMed ID: 11535128
    [Abstract] [Full Text] [Related]

  • 22. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May 15; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 23. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.
    Cubellis MV, Nolli ML, Cassani G, Blasi F.
    J Biol Chem; 1986 Dec 05; 261(34):15819-22. PubMed ID: 3023326
    [Abstract] [Full Text] [Related]

  • 24. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S, Lockett J, Meng Y, Biliran H, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.
    Cancer Res; 2006 Apr 15; 66(8):4173-81. PubMed ID: 16618739
    [Abstract] [Full Text] [Related]

  • 25. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ.
    Int J Cancer; 1995 May 29; 61(5):597-600. PubMed ID: 7768629
    [Abstract] [Full Text] [Related]

  • 26. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG.
    Mol Biol Cell; 2001 May 29; 12(5):1467-79. PubMed ID: 11359936
    [Abstract] [Full Text] [Related]

  • 27. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
    Cubellis MV, Wun TC, Blasi F.
    EMBO J; 1990 Apr 29; 9(4):1079-85. PubMed ID: 2157592
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
    Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M.
    Recent Results Cancer Res; 2003 Apr 29; 162():43-63. PubMed ID: 12790320
    [Abstract] [Full Text] [Related]

  • 29. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE, Saunders DN, Ranson M.
    Breast Cancer Res; 2007 Apr 29; 9(1):R14. PubMed ID: 17257442
    [Abstract] [Full Text] [Related]

  • 30. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
    Gershteĭn ES, Kushlinskiĭ NE.
    Vestn Ross Akad Med Nauk; 1999 Apr 29; (8):58-61. PubMed ID: 10487126
    [Abstract] [Full Text] [Related]

  • 31. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
    Higazi AA, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, McCrae KR, Kounnas MZ, Strickland DK, Preissner KT, Lawler J, Cines DB.
    Blood; 1996 Jul 15; 88(2):542-51. PubMed ID: 8695802
    [Abstract] [Full Text] [Related]

  • 32. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H, Duarte R, Kleeff J, Fukuda A, Tang WH, Graber H, Schilling M, Zimmermann A, Korc M, Büchler MW.
    Surgery; 1998 Jul 15; 124(1):79-86. PubMed ID: 9663255
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
    Ellis V, Wun TC, Behrendt N, Rønne E, Danø K.
    J Biol Chem; 1990 Jun 15; 265(17):9904-8. PubMed ID: 2161846
    [Abstract] [Full Text] [Related]

  • 34. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T, Behrendt N, Ploug M.
    Stem Cells; 1997 Jun 15; 15(6):398-408. PubMed ID: 9402652
    [Abstract] [Full Text] [Related]

  • 35. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gänsbacher B, Schmitt M.
    Cancer Gene Ther; 2000 Feb 15; 7(2):292-9. PubMed ID: 10770639
    [Abstract] [Full Text] [Related]

  • 36. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H.
    J Biol Chem; 1991 Mar 15; 266(8):5147-52. PubMed ID: 1900515
    [Abstract] [Full Text] [Related]

  • 37. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
    Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H.
    FEBS Lett; 1994 Jan 10; 337(2):131-4. PubMed ID: 8287966
    [Abstract] [Full Text] [Related]

  • 38. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J, Link J, Todd RF, Kramer MD.
    Exp Cell Res; 1994 Oct 10; 214(2):486-98. PubMed ID: 7925643
    [Abstract] [Full Text] [Related]

  • 39. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy.
    Pedersen TL, Plesner T, Horn T, Høyer-Hansen G, Sørensen S, Hansen NE.
    Ultrastruct Pathol; 2000 Oct 10; 24(3):175-82. PubMed ID: 10914429
    [Abstract] [Full Text] [Related]

  • 40. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M.
    Eur J Biochem; 1992 Jul 01; 207(1):177-83. PubMed ID: 1321039
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.